Samsung and GRAIL Announce Strategic Collaboration To Bring GRAIL’s Galleri® Multi-Cancer Early Detection Test to Asia

October 17, 2025

Samsung C&T (SCT), Samsung Electronics (SEC), and GRAIL, Inc. (Nasdaq: GRAL), today announced they have signed a binding Letter of Intent for a strategic collaboration to bring GRAIL’s GalleriⓇ multi-cancer early detection (MCED) test to key Asian markets. SCT and SEC have also agreed to invest $110 million into GRAIL, a healthcare company whose mission is to detect cancer early when it can be cured, at a price of $70.05 per share of common stock.1

For more information, please see:
https://news.samsung.com/global/samsung-and-grail-announce-strategic-collaboration-to-bring-grails-galleri-multi-cancer-early-detection-test-to-asia